Inbrija 42 mg/1 (Levodopa CAPSULE) 42 mg/1

Inbrija 42 mg capsules are an inhaled form of levodopa, designed for the treatment of Parkinson's disease. This medication is used to manage symptoms such as tremors, stiffness, and difficulty moving. Ideal for those seeking convenient, rapid relief.

Strength

42 mg/1

Pack Size

23 BLISTER PACK in 1 CARTON (10144-342-92) / 4 CAPSULE in 1 BLISTER PACK (10144-342-01)

Manufacturer / TM Owner

Merz Pharmaceuticals, LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Inbrija 42 mg capsules are primarily used to treat symptoms of Parkinson's disease, including tremors, rigidity, and slow movement. This medication is designed for inhalation, providing a quick onset of action. It is often used when oral medications are not providing sufficient relief or when symptoms return between doses.

Side Effects

Common effects of Inbrija 42 mg capsules may include dizziness, nausea, and cough. Some users may experience dry mouth or headache. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Precautions & Warnings

Inbrija 42 mg capsules should be used with caution in individuals with a history of heart, lung, or liver conditions. It is important to follow the prescribed dosage and administration instructions carefully. Always store the medication in a cool, dry place and keep it out of reach of children.

Avoid Interactions

Inbrija 42 mg capsules may interact with other medications, including those that affect the central nervous system. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol should be avoided while using this medication.

Frequently Asked Questions

Inbrija is used to manage symptoms of Parkinson's disease, such as tremors, stiffness, and difficulty moving.

Inbrija is administered via inhalation using the provided inhaler device. Follow the instructions provided by your healthcare provider.

Common side effects may include dizziness, nausea, cough, dry mouth, and headache.

Inbrija may interact with other medications, so it is important to consult your healthcare provider before combining it with other drugs.

Inbrija should be stored in a cool, dry place, away from direct sunlight and out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.